The chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP) and hyperkalemia (HK) market is poised to grow at a compound annual growth rate of 4.4%, from $2.6bn in 2024 to $4bn in 2034 across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US), according to GlobalData’s recently published report, Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment and Forecast.
This modest growth will be driven by the increase in prevalent cases of CKD-HPT, HP and HK during the forecast period. The overall diagnosed prevalence of CKD-HPT, HP and HK cases is expected to increase at an annual growth rate of 0.86%.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
With an estimated $1.5 billion in drug sales, the US dominated the CKD-HPT, HP and HK market in 2024, representing 59.7% of sales in the 7MM. GlobalData expects the US to remain as the leading market throughout the forecast period, generating sales of $2.5 billion in 2034, representing 63% of the overall market across the 7MM. This dominant position is a result of the significantly higher costs of marketed products in the US and a high diagnosed prevalence there.
Overall, the level of unmet need in the CKD-HPT, HP and HK market is high, and the greatest need is for improved compliance and improved tolerability. The currently available drug classes consist of calcimimetics, phosphate binders and potassium binders. Key opinion leaders (KOLs) interviewed by GlobalData noted that adherence to phosphate binders remains a big issue, most prominently in relation to the pill burden and pill size of phosphate binders at present. While the potential launch of three late-stage pipeline agents will increase the number of pharmacological treatment options that can be offered to CKD-HPT and CKD-HP patients, some patients may not benefit from them due to the challenges associated with gaining favourable reimbursement due to their anticipated high annual cost of therapy.
While the CKD-HPT, HP and HK market is projected to grow during the forecast period across the 7MM, it will face some challenges that will curtail its growth. Potential barriers to growth of the global CKD-HPT, HP and HK market include the loss of exclusivity of several key branded products that are expected to face patent and data exclusivity expiration, leading to brand erosion due to the emergence of generics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
